Welcome to our dedicated page for Arkema news (Ticker: ARKAY), a resource for investors and traders seeking the latest updates and insights on Arkema stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arkema's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arkema's position in the market.
Arkema plans to divest its epoxides business to Cargill for approximately $38.8 million, which reflects about 10 times the historical EBITDA. The epoxides business, generating sales of around $40 million, focuses on bio-based specialty products with limited integration into Arkema's core operations. The transaction aims to reposition Arkema towards Specialty Materials, enhancing its growth potential in industrial markets. The deal is expected to close in Q4 2021.
Arkema has announced a share buyback program conducted from September 13 to September 17, 2021. The total volume of shares repurchased amounted to 129,126 shares at a weighted average price of €115.11 per share. Transactions were executed under the regulation (EU) No 596/2014. The buyback reflects Arkema's commitment to enhancing shareholder value. Detailed information is accessible on their website.
Summary not available.
On August 31, 2021, Arkema reported the total number of shares and voting rights for its stock listed on Euronext Paris. The total number of shares stood at 76,736,476, with total voting rights including shares held by the company at 81,161,025. When excluding shares held by the company, the total voting rights increased to 85,145,973.
Arkema has conducted share buyback transactions from August 30 to September 3, 2021, totaling 33,417 shares. The average purchase price was approximately €110.28 per share. Notable transactions include the acquisition of 15,028 shares on September 3 at an average price of €111.81. Additional purchases included 9,784 shares on August 30 at €108.07 and 1,324 shares at €107.91 on the same date. For detailed information, visit Arkema's investor relations page.
Arkema has conducted share buyback transactions from 23 to 27 August 2021, adhering to EU regulations. A total of 107,612 shares were repurchased at an average price of €106.27 each. The company executed these transactions across various market identifiers, enhancing shareholder value through this strategic financial maneuver.
Arkema has announced the acquisition of Ashland’s Performance Adhesives business for an enterprise value of US$1,650 million, aligning with its strategy to become a pure Specialty Materials player by 2024. The business generated sales of approximately US$360 million in 2021 with an EBITDA margin above 25%. Synergies from the acquisition are expected to provide significant value, reducing the EV/EBITDA multiple to 8.7 by 2026. This deal aims for an EBITDA margin above 17% by 2024, enhancing Arkema's growth in high-performance adhesive solutions.
Arkema announced its share capital and voting rights as of July 31, 2021. The total number of shares stands at 76,736,476, while the total voting rights, including shares held by the company, amount to 87,229,105. Excluding shares held by the company, the total voting rights are recorded at 85,500,910. This data provides insights into the company's equity structure, which is crucial for shareholders and potential investors.
Arkema has conducted a series of share buyback transactions from August 16 to August 20, 2021. A total of 98,159 shares were repurchased at an average price of €107.26. Notably, on August 19 alone, 22,790 shares were acquired at an average price of €106.84. The buyback aligns with Article 5 of Regulation (EU) No 596/2014, signaling Arkema's commitment to returning value to shareholders. Detailed information is available on their investor relations website.